Module 1 (US) — Administrative & US Prescribing Information — GLPI-103
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The US administrative content plus the US Prescribing Information (USPI) — the FDA-format drug label.
Why it exists. A marketing application must propose the exact label under which the drug would be sold. The USPI follows the FDA Physician Labeling Rule structure (Highlights, Indications, Dosage, Warnings, Adverse Reactions, etc.) and is negotiated with the agency at approval.
How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.
Format & governing standard. eCTD US regional · 21 CFR 201.57 (PLR) · 21 CFR 208 (Medication Guide)
Module 1 (US) — Administrative & US Prescribing Information — GLPI-103
| Field | Value |
|---|---|
| Document ID | M1-US |
| Version | 2.0 (full) |
| Compound | GLPI-103 (GLP-1/APJ dual agonist) |
| Region | FDA (US) — NDA Module 1 |
| Standard | eCTD US regional · 21 CFR 201.57 (PLR) · 21 CFR 208 (Medication Guide) |
| Confidentiality | Confidential |
Region-specific administrative content and the US Prescribing Information (USPI) in Physician Labeling Rule format (Highlights + Full Prescribing Information). Clinical figures trace to CSR-301 (
outputs/).[MOCK]administrative identifiers.
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Regulatory Affairs (US) | Initial Module 1 + USPI |
| 2.0 | 2026-06-29 | Regulatory Affairs (US) | Full USPI — Highlights + FPI sections 1–17 |
1.1 Cover Letter [MOCK]
Virtual Biopharma Inc. submits this New Drug Application for GLPI-103 (intravenous and oral) for the treatment of adults with type 2 diabetes mellitus inadequately controlled on metformin. Enclosed are Form FDA 356h, the proposed USPI and Medication Guide, financial disclosure certifications, and eCTD Modules 2–5.
1.2 Application Form (Form FDA 356h) — summary [MOCK]
Applicant: Virtual Biopharma Inc. · Proposed proprietary name: (TBD) · Established name: GLPI-103 · Dosage forms/strengths: solution for injection (IV, once weekly); tablet (oral, once daily) · Proposed indication: T2DM as adjunct to diet and exercise.
1.3 Administrative & Regulatory
Patent and exclusivity information, debarment certification, financial disclosure (Forms FDA 3454/3455), user-fee cover sheet, and field-copy certification are provided per 356h (not reproduced here). An environmental assessment / claim of categorical exclusion is provided per 21 CFR 25.
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use GLPI-103 safely and effectively. See full prescribing information for GLPI-103.
WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning.
- In rodents, GLP-1 receptor agonists cause thyroid C-cell tumors. It is unknown whether GLPI-103 causes such tumors, including medullary thyroid carcinoma (MTC), in humans (5.1).
- GLPI-103 is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) (4).
Indications and Usage (1): GLPI-103 is a GLP-1/APJ receptor dual agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on metformin. Dosage and Administration (2): IV: 1 mg once weekly, titrated (1→2→4 mg). Oral: 2 mg once daily, titrated (2→4→8 mg). Titrate to manage gastrointestinal tolerability. Contraindications (4): Personal/family history of MTC or MEN 2; prior serious hypersensitivity. Warnings and Precautions (5): Thyroid C-cell tumors; acute pancreatitis; gastrointestinal adverse reactions; hypoglycemia with concomitant insulin secretagogues; cardiovascular/heart-rate monitoring.
FULL PRESCRIBING INFORMATION
1. Indications and Usage
The US Prescribing Information is not marketing copy — it is the legally approved statement of what the drug is for and how to use it, agreed with the FDA at approval. 'Indications and Usage' is the precise disease and population the drug may be promoted for.
GLPI-103 is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on metformin. Limitations of use: not for type 1 diabetes; not studied in patients with a history of pancreatitis.
2. Dosage and Administration
- Intravenous (Arm A regimen): initiate at 1 mg once weekly; increase to 2 mg at Week 4 and to the maintenance dose of 4 mg once weekly at Week 8.
- Oral: initiate at 2 mg once daily; increase to 4 mg at Week 4 and to the maintenance dose of 8 mg once daily at Week 8; administer per the food/water instructions.
- Titration/tolerability: if gastrointestinal symptoms are not tolerated, delay the dose increase or reduce by one level and re-attempt escalation.
- Continue background metformin.
4. Contraindications
GLPI-103 is contraindicated in patients with: a personal or family history of medullary thyroid carcinoma or MEN 2; and a prior serious hypersensitivity reaction to GLPI-103.
5. Warnings and Precautions
The safety findings from the whole program end up here, distilled into the warnings a prescriber reads. It is the practical payoff of all the safety analysis — turned into guidance at the point of care.
5.1 Thyroid C-cell tumors — see Boxed Warning; counsel patients regarding symptoms of thyroid tumors. 5.2 Acute pancreatitis — discontinue promptly if pancreatitis is suspected; do not restart if confirmed. 5.3 Gastrointestinal adverse reactions — nausea, vomiting, and diarrhea are common; severe events may cause dehydration and acute kidney injury; titrate to mitigate. 5.4 Hypoglycemia with concomitant use of insulin secretagogues or insulin — consider reducing the secretagogue/insulin dose. 5.5 Cardiovascular and heart rate — monitor heart rate and cardiovascular status given the mechanism.
6. Adverse Reactions
In the Phase 3 trial (GLPI103-301, N=900), the most common adverse reactions (≥5%) were gastrointestinal. Nausea occurred in 32.3% of patients receiving GLPI-103 IV versus 21.4% receiving the comparator (p=0.003); vomiting, diarrhea, and decreased appetite were also reported. Adverse reactions were predominantly mild to moderate; 10 serious adverse events and 2 deaths (none treatment-related) were reported in the dataset (6.1; CSR-301 §12).
7. Drug Interactions
GLPI-103 delays gastric emptying and may affect the absorption of concomitant oral medications; clinically relevant pharmacokinetic interactions are not expected based on its peptide disposition. Use with insulin secretagogues/insulin increases hypoglycemia risk (5.4).
8. Use in Specific Populations
8.1 Pregnancy — limited data; use only if the potential benefit justifies the risk. 8.2 Lactation — no data; consider benefit/risk. 8.4 Pediatric use — safety and effectiveness not established. 8.5 Geriatric use — consistent with the overall population. 8.6 Renal impairment — not studied in severe impairment (eGFR <45 excluded). 8.7 Hepatic impairment — not studied in significant impairment (ALT/AST >3×ULN excluded).
11. Description
GLPI-103 is a synthetic peptide dual agonist of the GLP-1 and apelin (APJ) receptors, supplied as a solution for intravenous injection and as a tablet for oral administration (M3).
12. Clinical Pharmacology
12.1 Mechanism of action — dual agonism of the GLP-1 and APJ receptors. 12.2 Pharmacodynamics — glucose-dependent insulinotropic and weight effects; cardiometabolic biomarker effects. 12.3 Pharmacokinetics — long half-life (once-weekly IV); oral bioavailability with permeation enhancer; proteolytic catabolism; low drug-interaction potential (M2.7.2).
13. Nonclinical Toxicology
13.1 Carcinogenesis, mutagenesis, impairment of fertility — class-appropriate thyroid C-cell monitoring; negative genotoxicity; reproductive findings limited to maternal effects (M4-2.3).
14. Clinical Studies
In GLPI103-301, GLPI-103 (IV and oral) was superior to oral semaglutide in HbA1c reduction at Week 52 (IV −0.68%, oral −0.34% versus comparator; both p<0.001), with greater weight reduction and higher responder rates (M2.7.3; CSR-301 §11).
16. How Supplied/Storage and Handling
Supplied as described in Module 3; store per label.
17. Patient Counseling Information / Medication Guide
Advise patients of the risk of thyroid tumors and symptoms of pancreatitis; counsel on managing gastrointestinal effects through titration and on hypoglycemia precautions with concomitant glucose-lowering medicines. A Medication Guide is dispensed with each prescription (21 CFR 208).
Comments (0)
No comments yet. Be the first to say something!